Highlights Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Real-time Estimate Cboe BZX Other stock markets 07:36:19 14/05/2024 pm IST			5-day change	1st Jan Change
2.235 ^USD	+0.22%		-4.22%	-24.08%

07/05	Investor Sentiment Muted After Rate Cut Optimism, Stifling US Equity Futures Pre-Bell	MT
07/05	Top Premarket Gainers	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Premarket Gainers	07/05	MT
Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q1 Revenue $137.7M, vs. Street Est of $83.9M	07/05	MT
Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q1 EPS $0.34, vs. Street Est of $-0.01	07/05	MT
Esperion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Sector Update: Health Care Stocks Steady Premarket Monday	25/03	MT
Top Premarket Gainers	25/03	MT
U.S. FDA Approves Broad New Labels for Esperion?s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	23/03	CI
Esperion Therapeutics Shares Rise After US FDA Expands Labels for Nexletol, Nexlizet	23/03	MT
Esperion, Daiichi Get EU Committee Recommendation For Nilemdo, Nustendi Label Update	22/03	MT
Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Announces CHMP Adopts Positive Opinions for the Label Update of Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination	22/03	CI
North American Morning Briefing : Stock Futures -2-	27/02	DJ
Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q4 Revenue $32.3M, vs. Street Est of $28.7M	27/02	MT
Esperion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02	CI
Esperion Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02	CI
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Tech Stocks Gains	19/01	MT
Esperion Therapeutics, Daiichi Sankyo Europe Settle Commercial Dispute With $125 Million Amendment in Collaboration	03/01	MT
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation	03/01	CI
U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL®? (bempedoic Acid) Tablet and NEXLIZET®? (bempedOic Acid and ezetimibe) Tablet	14/12	CI
Partners Announce Transform Trial to Evaluate Personalized Heart Disease Care Strategies At American Heart Association 2023	11/11	CI
Esperion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Highlights

Filters